Kiromic Biopharma Inc (KRBP)

OTC Markets
Currency in USD
Disclaimer
0.220
-0.070
(-24.10%)
Closed
Trading near 52-week Low
Day's Range
0.220
0.220
52 wk Range
0.220
15.300
Volume
1,807
Prev. Close
0.29
Open
0.22
Day's Range
0.22-0.22
52 wk Range
0.22-15.3
Volume
1,807
Average Volume (3m)
61,461
1-Year Change
-97.23%
Shares Outstanding
1,176,260
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

1.710
TIVC
-7.07%
1.03
TKLF
-1.90%
0.8900
MF
+3.49%
0.5980
HOOK
-0.17%
How do you feel today about KRBP?
Vote to see community's results!
or

Kiromic Biopharma Inc Company Profile

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Income Statement